30 closest matches · ranked by relevance
Pigmented Villonodular Synovitis · PVNS · Giant Cell Tumor of the Tendon Sheath
Primary: Change in Pigmented Villonodular Synovitis (PVNS) Tumor Size — -4222.8; -668.5; -9998.4; -38002.1 mm3
Pigmented Villonodular Synovitis · Tenosynovial Giant Cell Tumor
Primary: The Incidence of Grade 3 and Grade 4 Adverse Events (AEs) and Defined as Dose-limiting Toxicities (DLTs) in Phase 1 — 0; 0; 0 Participants
Pigmented Villonodular Synovitis · Diffuse-type Giant Cell Tumor · Tenosynovial Giant Cell Tumor
Primary: Percentage of Participants With Progression Free Survival — 82 percentage of participants with PFS
Pigmented Villonodular Synovitis · Giant Cell Tumors of the Tendon Sheath · Tenosynovial Giant Cell Tumor
Primary: Percentage of Participants With Symptomatic, Locally Advanced Tenosynovial Giant Cell Tumor (TGCT) Achieving Complete or Partial Response to Pexidartinib Compared With…
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Palmoplantaris Pustulosis
Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Psoriasis · Melanoma · Non-melanoma Skin Cancer
Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants
Tenosynovial Giant Cell Tumor · Pigmented Villonodular Synovitis (PVNS)
Primary: Number of Participants With Treatment-emergent Adverse Events — 7; 2 Participants
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
Ganglion of Wrist
Primary: Number of Participants With a Recurrence of Ganglia — 8; 5 Participants
Systemic Sclerosis
Primary: Raynaud's Condition Scale — 5; 5; 6.5; 3 score on a scale — p=0.256
Port Wine Stains
Primary: Blanching of Port Wine Stain Birthmark — 16 participants
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Pemphigus
Primary: Participant Response to Treatment at Week 18 — 1; 1 Participants — p=1.00
Vitreous Inflammation
Primary: Vitreous Prostaglandin E2 Levels — 369.38; 869.16 pg/mL
Psoriasis · Cardiovascular Disease
Primary: Change in Vascular Inflammation — -3.8 percentage change
Vestibular Schwannoma
Primary: Surgeon Predicted Use of Fluorescein Sodium in Future Cases — 0; 0; 4; 3 participants
Lymphatic Malformations
Primary: Number of Participants With Clinical Success at 1 to 6 Months Post-Therapy as Assessed by Imaging — 57 Participants
Osteochondritis Dissecans
Primary: Greater Cartilage Healing Measured by Glycosaminoglycan Content on dGEMRIC MRI
Anterior Knee Pain Syndrome
Primary: Number of Participants With Successful Recording. — 2; 3 Participants
Pyoderma Gangrenosum · Crohn's Disease · Ulcerative Colitis
Primary: The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease — 1 participants
Otitis Media Chronic · Temporal Bone
Primary: Change in Inflammation Surface Area. — 100; 100; 43; 135 percentage of the baseline surface
Osteoarthritis (OA)
Primary: Safety - Number of Participants With Treatment-Emergent Serious Adverse Events — 0; 0; 0; 0 Participants
Sarcoma, Soft Tissue
Primary: Progression-free Survival (PFS) — 7.0; 20.0 weeks — p=<0.001
Painful Digital Neuroma
Primary: Static 2-point Discrimination Test — 7.3 mm
Neovascular Macular Degeneration
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last…
Fibrodysplasia Ossificans Progressiva
Primary: Annualized New Heterotopic Ossification (HO) — 9427.1; 23720.2 cubic millimeters (mm^3)
Tenosynovial Giant Cell Tumor
Primary: Number of Treatment-Free Participants at 12 Months In The Treatment-free/Re-treatment Cohort — 8 Participants